HIGH GRADE SEROUS ADENOCARCINOMA OF OVARY
Clinical trials for HIGH GRADE SEROUS ADENOCARCINOMA OF OVARY explained in plain language.
Never miss a new study
Get alerted when new HIGH GRADE SEROUS ADENOCARCINOMA OF OVARY trials appear
Sign up with your email to follow new studies for HIGH GRADE SEROUS ADENOCARCINOMA OF OVARY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug IMGN151 shows promise in early trial for Tough-to-Treat cancers
Disease control OngoingThis early-phase study tests a new drug called IMGN151 in 256 adults with recurrent gynaecological cancers (ovarian, endometrial, cervical, and related cancers). The drug is designed to target and kill cancer cells while sparing healthy ones. The main goals are to check safety, f…
Matched conditions: HIGH GRADE SEROUS ADENOCARCINOMA OF OVARY
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated May 17, 2026 04:42 UTC
-
New hope for tough ovarian cancer: drug combo trial shows promise
Disease control OngoingThis study tests whether a new drug (ONC-392) combined with an existing immunotherapy (pembrolizumab) can shrink tumors or slow disease in people with ovarian cancer that no longer responds to platinum chemotherapy. About 58 adults with high-grade serous ovarian, primary peritone…
Matched conditions: HIGH GRADE SEROUS ADENOCARCINOMA OF OVARY
Phase: PHASE2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New pill shows promise for Hard-to-Treat ovarian cancer
Disease control OngoingThis study tests a new daily pill called sovilnesib for people with advanced ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to find the safest and most effective dose. About 120 participants will receive different doses to measure side effects an…
Matched conditions: HIGH GRADE SEROUS ADENOCARCINOMA OF OVARY
Phase: PHASE1 • Sponsor: Volastra Therapeutics, Inc. • Aim: Disease control
Last updated May 11, 2026 20:37 UTC
-
New dual-immunotherapy combo tested in advanced cancers
Disease control OngoingThis early-phase study tests a new drug, AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) into one treatment for people with advanced solid tumors that have stopped responding to standard therapies. The main goal is to find the safest dose and check for…
Matched conditions: HIGH GRADE SEROUS ADENOCARCINOMA OF OVARY
Phase: PHASE1 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated May 08, 2026 12:01 UTC